{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:34:47Z","timestamp":1760783687801},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T00:00:00Z","timestamp":1370649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00415-013-6980-5","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T03:07:41Z","timestamp":1370574461000},"page":"2279-2285","source":"Crossref","is-referenced-by-count":18,"title":["Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease"],"prefix":"10.1007","volume":"260","author":[{"given":"Thomas","family":"Hundsberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Rohrbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai M.","family":"R\u00f6sler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,8]]},"reference":[{"key":"6980_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","volume":"40","author":"AANEM practice topic","year":"2009","unstructured":"AANEM practice topic (2009) Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve 40:149\u2013160","journal-title":"Muscle Nerve"},{"key":"6980_CR2","first-page":"132","volume":"3","author":"A Amalfitano","year":"2001","unstructured":"Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA III, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med 3:132\u2013138","journal-title":"Genet Med"},{"key":"6980_CR3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di IG, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4\u00a0years. J Neurol 259:952\u2013958","journal-title":"J Neurol"},{"key":"6980_CR4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.0b013e31818da91e","volume":"71","author":"B Bembi","year":"2008","unstructured":"Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, Musumeci O, Parenti G, Ravaglia S, Seidita F, Toscano A, Vianello A (2008) Diagnosis of glycogenosis type II. Neurology 71:S4\u201311","journal-title":"Neurology"},{"key":"6980_CR5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.0b013e31818da93f","volume":"71","author":"B Bembi","year":"2008","unstructured":"Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, Musumeci O, Parenti G, Ravaglia S, Seidita F, Toscano A, Vianello A (2008) Management and treatment of glycogenosis type II. Neurology 71:S12\u2013S36","journal-title":"Neurology"},{"key":"6980_CR6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33:727\u2013735","journal-title":"J Inherit Metab Dis"},{"key":"6980_CR7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(08)60876-4","volume":"371","author":"BM Buckley","year":"2008","unstructured":"Buckley BM (2008) Clinical trials of orphan medicines. Lancet 371:2051\u20132055","journal-title":"Lancet"},{"key":"6980_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT (2012) Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45:319\u2013333","journal-title":"Muscle Nerve"},{"key":"6980_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ymgme.2011.09.012","volume":"104","author":"JM Vries de","year":"2011","unstructured":"de Vries JM, Brugma JD, Ozkan L, Steegers EA, Reuser AJ, van Doorn PA, van der Ploeg AT (2011) First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. Mol Genet Metab 104:552\u2013555","journal-title":"Mol Genet Metab"},{"key":"6980_CR10","unstructured":"Deegan P (2007) Guidelines for the investigation and management of late onset acid maltase deficiency (type II glycogen storage disease\/Pompe disease); Version 3"},{"key":"6980_CR11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.21376","volume":"40","author":"JL Goldstein","year":"2009","unstructured":"Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, Peterson D, Millington DS, Kishnani PS, Bali DS (2009) Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve 40:32\u201336","journal-title":"Muscle Nerve"},{"key":"6980_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","volume":"6","author":"D Gungor","year":"2011","unstructured":"Gungor D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, Hagemans ML (2011) Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 6:34","journal-title":"Orphanet J Rare Dis"},{"key":"6980_CR13","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT (2005) Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64:2139\u20132141","journal-title":"Neurology"},{"key":"6980_CR14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, Van der Ploeg AT (2005) Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain 128:671\u2013677","journal-title":"Brain"},{"key":"6980_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CND.0b013e318176dbe4","volume":"9","author":"LW Katzin","year":"2008","unstructured":"Katzin LW, Amato AA (2008) Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. J Clin Neuromuscul Dis 9:421\u2013431","journal-title":"J Clin Neuromuscul Dis"},{"key":"6980_CR16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, Gruskin D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, Bauer MS, Jokic M, Tsai CE, Tsai BW, Morgan C, O\u2019Meara T, Richards S, Tsao EC, Mandel H (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329\u2013335","journal-title":"Pediatr Res"},{"key":"6980_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S, Davison M, Corzo D, Chen YT (2006) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89\u201397","journal-title":"J Pediatr"},{"key":"6980_CR18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O\u2019Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS (2006) Pompe disease diagnosis and management guideline. Genet Med 8:267\u2013288","journal-title":"Genet Med"},{"key":"6980_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","volume":"15","author":"L Klinge","year":"2005","unstructured":"Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Gorlinger K, Wallot M, Richards S, Voit T (2005) Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15:24\u201331","journal-title":"Neuromuscul Disord"},{"key":"6980_CR20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0b013e318228c0ea","volume":"77","author":"K Laloui","year":"2011","unstructured":"Laloui K, Wary C, Carlier RY, Hogrel JY, Caillaud C, Laforet P (2011) Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat? Neurology 77:594\u2013595","journal-title":"Neurology"},{"key":"6980_CR21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jpeds.2009.07.006","volume":"155","author":"JC Llerena Jr","year":"2009","unstructured":"Llerena JC Jr, Horovitz DM, Marie SK, Porta G, Giugliani R, Rojas MV, Martins AM (2009) The Brazilian consensus on the management of Pompe disease. J Pediatr 155:S47\u2013S56","journal-title":"J Pediatr"},{"key":"6980_CR22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10545-009-9003-z","volume":"33","author":"Z Lukacs","year":"2010","unstructured":"Lukacs Z, Nieves CP, Mengel E, Hartung R, Beck M, Deschauer M, Keil A, Santer R (2010) Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening. J Inherit Metab Dis 33:43\u201350","journal-title":"J Inherit Metab Dis"},{"key":"6980_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","volume":"79","author":"F Martiniuk","year":"1998","unstructured":"Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, Codd WJ, Hanna B, Alcabes P, Raben N, Plotz P (1998) Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79:69\u201372","journal-title":"Am J Med Genet"},{"key":"6980_CR24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2010.12.001","volume":"41","author":"R Nair","year":"2011","unstructured":"Nair R, Aggarwal R, Khanna D (2011) Methods of formal consensus in classification\/diagnostic criteria and guideline development. Semin Arthritis Rheum 41:95\u2013105","journal-title":"Semin Arthritis Rheum"},{"key":"6980_CR25","unstructured":"Ontario Ministry of health and long-term care (2009) Ontario public drug programs, exceptional access program, Myozyme (alglucosidase-alfa)-adult\/late onset Pompe disease reimbursement guideline; Version 1"},{"key":"6980_CR26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2174\/138920111795542606","volume":"12","author":"G Parenti","year":"2011","unstructured":"Parenti G, Andria G (2011) Pompe disease: from new views on pathophysiology to innovative therapeutic strategies. Curr Pharm Biotechnol 12:902\u2013915","journal-title":"Curr Pharm Biotechnol"},{"key":"6980_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/mus.21304","volume":"40","author":"A Pichiecchio","year":"2009","unstructured":"Pichiecchio A, Poloni GU, Ravaglia S, Ponzio M, Germani G, Maranzana D, Costa A, Repetto A, Tavazzi E, Danesino C, Moglia A, Bastianello S (2009) Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? Muscle Nerve 40:122\u2013125","journal-title":"Muscle Nerve"},{"key":"6980_CR28","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","volume":"10","author":"N Raben","year":"2001","unstructured":"Raben N, Lu N, Nagaraju K, Rivera Y, Lee A, Yan B, Byrne B, Meikle PJ, Umapathysivam K, Hopwood JJ, Plotz PH (2001) Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 10:2039\u20132047","journal-title":"Hum Mol Genet"},{"key":"6980_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.31317","volume":"160","author":"N Raben","year":"2012","unstructured":"Raben N, Wong A, Ralston E, Myerowitz R (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 160:13\u201321","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"6980_CR30","first-page":"127","volume":"2","author":"J Rankin","year":"1957","unstructured":"Rankin J (1957) Cerebral vascular accidents in patients over the age of 60. I. General considerations. Scott Med J 2:127\u2013136","journal-title":"I. General considerations. Scott Med J"},{"key":"6980_CR31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10545-010-9204-5","volume":"33","author":"S Ravaglia","year":"2010","unstructured":"Ravaglia S, Pichiecchio A, Ponzio M, Danesino C, Saeidi GK, Poloni GU, Toscano A, Moglia A, Carlucci A, Bini P, Ceroni M, Bastianello S (2010) Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J Inherit Metab Dis 33:737\u2013745","journal-title":"J Inherit Metab Dis"},{"key":"6980_CR32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, Muller-Felber W, Glocker FX, Spranger M, Deschauer M (2012) 36\u00a0months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35:837\u2013845","journal-title":"J Inherit Metab Dis"},{"key":"6980_CR33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","volume":"5","author":"B Schoser","year":"2008","unstructured":"Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II\/Pompe disease. Neurotherapeutics 5:569\u2013578","journal-title":"Neurotherapeutics"},{"key":"6980_CR34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2165\/11635320-000000000-00000","volume":"72","author":"S Simoens","year":"2012","unstructured":"Simoens S, Cassiman D, Dooms M, Picavet E (2012) Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs 72:1437\u20131443","journal-title":"Drugs"},{"key":"6980_CR35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajmg.c.31323","volume":"160","author":"GA Spiridigliozzi","year":"2012","unstructured":"Spiridigliozzi GA, Heller JH, Kishnani PS (2012) Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. Am J Med Genet C Semin Med Genet 160:22\u201329","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"6980_CR36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Muller-Felber W, Mengel E, Spranger M, Schoser B (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91\u201397","journal-title":"J Neurol"},{"key":"6980_CR37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260:951\u2013959","journal-title":"J Neurol"},{"key":"6980_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","volume":"7","author":"NA Beek van der","year":"2012","unstructured":"van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber KG, Verschuuren JJ, Reuser AJ, van der Ploeg AT, van Doorn PA (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88","journal-title":"Orphanet J Rare Dis"},{"key":"6980_CR39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","volume":"19","author":"NA Beek van der","year":"2009","unstructured":"van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, van der Ploeg AT, van Doorn PA, Wokke JH (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19:113\u2013117","journal-title":"Neuromuscul Disord"},{"key":"6980_CR40","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg van der","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372:1342\u20131353","journal-title":"Lancet"},{"key":"6980_CR41","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg van der","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362:1396\u20131406","journal-title":"N Engl J Med"},{"key":"6980_CR42","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg van der","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372:1342\u20131353","journal-title":"Lancet"},{"key":"6980_CR43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","volume":"13","author":"RY Wang","year":"2011","unstructured":"Wang RY, Bodamer OA, Watson MS, Wilcox WR (2011) Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 13:457\u2013484","journal-title":"Genet Med"},{"key":"6980_CR44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","volume":"13","author":"RY Wang","year":"2011","unstructured":"Wang RY, Bodamer OA, Watson MS, Wilcox WR (2011) Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 13:457\u2013484","journal-title":"Genet Med"},{"key":"6980_CR45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymgme.2007.09.006","volume":"93","author":"B Winchester","year":"2008","unstructured":"Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, Cupler E, Deschauer M, Fumic K, Jackson M, Kishnani P, Lacerda L, Ledvinova J, Lugowska A, Lukacs Z, Maire I, Mandel H, Mengel E, Muller-Felber W, Piraud M, Reuser A, Rupar T, Sinigerska I, Szlago M, Verheijen F, van Diggelen OP, Wuyts B, Zakharova E, Keutzer J (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93:275\u2013281","journal-title":"Mol Genet Metab"},{"key":"6980_CR46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","volume":"252","author":"LP Winkel","year":"2005","unstructured":"Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT (2005) The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases. J Neurol 252:875\u2013884","journal-title":"J Neurol"},{"key":"6980_CR47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Jiang JL, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ, Lee K, Kudo M, Canfield WM, Edmunds T, Jiang C, Mattaliano RJ, Cheng SH (2009) Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 17:954\u2013963","journal-title":"Mol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-013-6980-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-013-6980-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-013-6980-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T18:12:36Z","timestamp":1563127956000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-013-6980-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,8]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["6980"],"URL":"https:\/\/doi.org\/10.1007\/s00415-013-6980-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,8]]}}}